When available, the Online Course format is included with the hard copy, eBook, or audio book formats!
Start Date: September 16, 2016
Expiration Date: September 15, 2019
Oral anticoagulants are indicated for the management of thrombotic conditions, namely, in the prevention of stroke and systemic embolization and in the treatment of venous thromboembolism. Within the past 6 years, the landscape of managing these conditions in the United States has changed dramatically.
The uptake of novel oral anticoagulants in clinical practice has been successful, although there are important drug and patient characteristics to consider when selecting among these therapies. This course is designed for pharmacists who are involved in decision making for oral anticoagulant selection or who take care of patients who have already been prescribed oral anticoagulants. The purpose of this course is to increase pharmacists’ knowledge of oral anticoagulants so that they can identify patients in whom therapy is indicated, assist in selecting the most appropriate option, and monitor and counsel the patient.
The focus of this course is on the newest oral anticoagulant drug therapies, their indications, and data supporting their use in clinical practice. Although warfarin has many uses outside of these focused indications, it will not be discussed within this course. This course begins with an overview of hemostasis and the process of thrombus formation. Next, risk assessment for thrombosis and bleeding is reviewed in the setting of atrial fibrillation and venous thromboembolism. An overview of the oral anti-coagulant prescribing information and key clinical trials follows. Finally, pearls for patient selection, monitoring, and counseling are provided.
Universal Activity Number (UAN) - 0607-0000-16-012-H01-P
Type of Activity - Knowledge
Topic Designator - 01
- Identify oral anticoagulants, their respective pharmacologic class, and their approved indications.
- Identify the current place in therapy of oral anticoagulants in the management of patients with atrial fibrillation and in prevention and treatment of venous thromboembolism (VTE).
- Describe evidence supporting the use of oral anticoagulants in patients with atrial fibrillation and in the prevention and treatment of VTE.
- Identify pertinent contraindications, side effects, drug interactions, monitoring parameters, and patient counseling points for oral anticoagulants.
- Identify reversal agents for oral anticoagulants.
Diana M. Sobieraj, PharmD, BCPS, earned her Doctor of Pharmacy degree from the University of Rhode Island and subsequently completed a pharmacy practice residency at Hartford Hospital/The University of Connecticut School of Pharmacy. After her training, Dr. Sobieraj joined the faculty at UCONN School of Pharmacy, where she has worked for the past 8 years. Currently, Dr. Sobieraj is an Assistant Professor in the Department of Pharmacy Practice in the tenure track. Her scholarly interests focus on comparative effectiveness and health outcomes research of anticoagulants and the treatment and prevention of thrombosis. Dr. Sobieraj has more than 40 publications in the peer-reviewed literature, including journals such as Annals of Internal Medicine, Journal of the American Geriatrics Society, International Journal of Cardiology, and Thrombosis Research. Dr. Sobieraj is a member of the American College of Clinical Pharmacy, the current Secretary/Treasurer of the American College of Clinical Pharmacy Health Outcomes PRN, and a member of the Community Advisory Panel of the American College of Clinical Pharmacy Practice-Based Research Network.
- Contact hours will be awarded for up to one (1) year from date of purchase or by the expiration date indicated above, whichever date comes first.
- You must score 75% or higher on the final exam and complete the course evaluation to pass this course and receive a certificate of completion.
- Through our review processes, Western Schools ensures that this course content is presented in a balanced, unbiased manner and is free from commercial influence. It is Western Schools’ policy not to accept commercial support.
- All persons involved in the planning and development of this course have disclosed no relevant financial relationships or other conflicts of interest related to the course content.